These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 26001708)

  • 1. A Large National Cohort Study of the Association between Bisphosphonates and Osteonecrosis of the Jaw in Patients with Osteoporosis: A Nested Case-control Study.
    Kwon JW; Park EJ; Jung SY; Sohn HS; Ryu H; Suh HS
    J Dent Res; 2015 Sep; 94(9 Suppl):212S-9S. PubMed ID: 26001708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
    Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
    PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gradual, but Not Sudden, Dose-Dependent Increase of ONJ Risk With Bisphosphonate Exposure: A Nationwide Cohort Study in Women With Osteoporosis.
    Park JH; Kwoen MJ; Lee JR; Kim KS; Lee HJ; Kim JW; Lee H
    Front Endocrinol (Lausanne); 2021; 12():774820. PubMed ID: 34956086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The national-scale cohort study on bisphosphonate-related osteonecrosis of the jaw in Taiwan.
    Yuh DY; Chang TH; Huang RY; Chien WC; Lin FG; Fu E
    J Dent; 2014 Oct; 42(10):1343-52. PubMed ID: 24907558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users.
    Eiken PA; Prieto-Alhambra D; Eastell R; Abrahamsen B
    Osteoporos Int; 2017 Oct; 28(10):2921-2928. PubMed ID: 28664276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis.
    Tennis P; Rothman KJ; Bohn RL; Tan H; Zavras A; Laskarides C; Calingaert B; Anthony MS
    Pharmacoepidemiol Drug Saf; 2012 Aug; 21(8):810-7. PubMed ID: 22711458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment.
    Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C
    J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures.
    Lapi F; Cipriani F; Caputi AP; Corrao G; Vaccheri A; Sturkenboom MC; Di Bari M; Gregori D; Carle F; Staniscia T; Vestri A; Brandi M; Fusco V; Campisi G; Mazzaglia G;
    Osteoporos Int; 2013 Feb; 24(2):697-705. PubMed ID: 22618266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons.
    Khan AA; Rios LP; Sándor GK; Khan N; Peters E; Rahman MO; Clokie CM; Dore E; Dubois S
    J Rheumatol; 2011 Jul; 38(7):1396-402. PubMed ID: 21498483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.
    Solomon DH; Mercer E; Woo SB; Avorn J; Schneeweiss S; Treister N
    Osteoporos Int; 2013 Jan; 24(1):237-44. PubMed ID: 22707065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study.
    Kim SH; Lee YK; Kim TY; Ha YC; Jang S; Kim HY
    Bone; 2021 Feb; 143():115650. PubMed ID: 32956854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
    Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
    J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and risk of osteonecrosis of the jaw among the Taiwan osteoporosis population.
    Lin TC; Yang CY; Kao Yang YH; Lin SJ
    Osteoporos Int; 2014 May; 25(5):1503-11. PubMed ID: 24515577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
    Kunchur R; Need A; Hughes T; Goss A
    J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notoriety bias in a database of spontaneous reports: the example of osteonecrosis of the jaw under bisphosphonate therapy in the French national pharmacovigilance database.
    de Boissieu P; Kanagaratnam L; Abou Taam M; Roux MP; Dramé M; Trenque T
    Pharmacoepidemiol Drug Saf; 2014 Sep; 23(9):989-92. PubMed ID: 24737486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
    Mavrokokki T; Cheng A; Stein B; Goss A
    J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.
    Chiu WY; Chien JY; Yang WS; Juang JM; Lee JJ; Tsai KS
    J Clin Endocrinol Metab; 2014 Aug; 99(8):2729-35. PubMed ID: 24758181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Risk Factors for Bisphosphonate-Associated Atypical Femoral Fractures and Osteonecrosis of the Jaw in a Pharmacovigilance Database.
    Bejhed RS; Kharazmi M; Hallberg P
    Ann Pharmacother; 2016 Aug; 50(8):616-24. PubMed ID: 27179251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.